Type i IFN inhibits alternative macrophage activation during mycobacterium tuberculosis infection and leads to enhanced protection in the absence of IFN-γ signaling

Journal of Immunology

Volumn 197, Issue 12, 2016, Pages 4714-4726

  Moreira Teixeira, Lúcia ^a,b   Sousa, Jeremy ^a,c   McNab, Finlay W ^b,g   Torrado, Egídio ^a   Cardoso, Filipa ^a   Machado, Henrique ^a   Castro, Flávia ^a   Cardoso, Vânia ^a   Gaifem, Joana ^a   Wu, Xuemei ^b   Appelberg, Rui ^c,d   Castro, António Gil ^a   O'Garra, Anne ^b,e   Saraiva, Margarida ^a,c,f  

^a UNIVERSITY OF MINHO   (Portugal)

^b THE FRANCIS CRICK INSTITUTE   (United Kingdom)

^c UNIVERSITY OF PORTO   (Portugal)

^d UNIVERSITY OF PORTO   (Portugal)

^e NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^f UNIVERSITY OF PORTO   (Portugal)

^g GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINASE 1; GAMMA INTERFERON; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERFERON; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR; ARG1 PROTEIN, MOUSE; ARGINASE; CYTOKINE; INTERFERON RECEPTOR; NOS2 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL GROWTH; BACTERIAL LOAD; BACTERIAL STRAIN; CONTROLLED STUDY; CORRELATIONAL STUDY; GENE EXPRESSION; IMMUNOPATHOLOGY; MACROPHAGE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; SURVIVAL; TH2 CELL; TUBERCULOSIS; ANIMAL; C57BL MOUSE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNOLOGY; KNOCKOUT MOUSE; LUNG; LUNG TUBERCULOSIS; MACROPHAGE ACTIVATION; METABOLISM; MICROBIOLOGY; MYCOBACTERIUM TUBERCULOSIS;

ANIMALS; ARGINASE; BACTERIAL LOAD; CYTOKINES; GENE EXPRESSION REGULATION; HUMANS; INTERFERON TYPE I; INTERFERON-GAMMA; LUNG; MACROPHAGE ACTIVATION; MACROPHAGES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYCOBACTERIUM TUBERCULOSIS; NITRIC OXIDE SYNTHASE TYPE II; RECEPTORS, INTERFERON; SIGNAL TRANSDUCTION; TH2 CELLS; TUBERCULOSIS, PULMONARY;

EID: 85002328285     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1600584     Document Type: Article

References (66)

1. World Health Organization. 2015. Global Tuberculosis Report 2015. World Health Organization, Geneva, Switzerland.
2. Kleinnijenhuis, J., M. Oosting, L. A. Joosten, M. G. Netea, and R. Van Crevel. 2011. Innate immune recognition of Mycobacterium tuberculosis. Clin. Dev. Immunol. 2011: 405310.
3. Flynn, J. L., and J. Chan. 2001. Immunology of tuberculosis. Annu. Rev. Immunol. 19: 93-129.
4. North, R. J., and Y. J. Jung. 2004. Immunity to tuberculosis. Annu. Rev. Immunol. 22: 599-623.
5. Cooper, A. M. 2009. Cell-mediated immune responses in tuberculosis. Annu. Rev. Immunol. 27: 393-422.
6. O'Garra, A., P. S. Redford, F. W. McNab, C. I. Bloom, R. J. Wilkinson, and M. P. Berry. 2013. The immune response in tuberculosis. Annu. Rev. Immunol. 31: 475-527.
7. Flynn, J. L., M. M. Goldstein, K. J. Triebold, J. Sypek, S. Wolf, and B. R. Bloom. 1995. IL-12 increases resistance of BALB/c mice to Mycobacterium tuberculosis infection. J. Immunol. 155: 2515-2524.
8. Cooper, A. M., J. Magram, J. Ferrante, and I. M. Orme. 1997. Interleukin 12 (IL-12) is crucial to the development of protective immunity in mice intravenously infected with Mycobacterium tuberculosis. J. Exp. Med. 186: 39-45.
9. Casanova, J. L., and L. Abel. 2002. Genetic dissection of immunity to mycobacteria: the human model. Annu. Rev. Immunol. 20: 581-620.
10. Cooper, A. M., D. K. Dalton, T. A. Stewart, J. P. Griffin, D. G. Russell, and I. M. Orme. 1993. Disseminated tuberculosis in interferon g gene-disrupted mice. J. Exp. Med. 178: 2243-2247.
11. Flynn, J. L., J. Chan, K. J. Triebold, D. K. Dalton, T. A. Stewart, and B. R. Bloom. 1993. An essential role for interferon g in resistance to Mycobacterium tuberculosis infection. J. Exp. Med. 178: 2249-2254.
12. MacMicking, J. D., R. J. North, R. LaCourse, J. S. Mudgett, S. K. Shah, and C. F. Nathan. 1997. Identification of nitric oxide synthase as a protective locus against tuberculosis. Proc. Natl. Acad. Sci. USA 94: 5243-5248.
13. Shi, L., Y. J. Jung, S. Tyagi, M. L. Gennaro, and R. J. North. 2003. Expression of Th1-mediated immunity in mouse lungs induces a Mycobacterium tuberculosis transcription pattern characteristic of nonreplicating persistence. Proc. Natl. Acad. Sci. USA 100: 241-246.
14. Scanga, C. A., V. P. Mohan, K. Tanaka, D. Alland, J. L. Flynn, and J. Chan. 2001. The inducible nitric oxide synthase locus confers protection against aerogenic challenge of both clinical and laboratory strains of Mycobacterium tuberculosis in mice. Infect. Immun. 69: 7711-7717.
15. Carmona, J., A. Cruz, L. Moreira-Teixeira, C. Sousa, J. Sousa, N. S. Osorio, A. L. Saraiva, S. Svenson, G. Kallenius, J. Pedrosa, et al. 2013. Mycobacterium tuberculosis strains are differentially recognized by TLRs with an impact on the immune response. PLoS One 8: e67277.
16. McNab, F., K. Mayer-Barber, A. Sher, A. Wack, and A. O'Garra. 2015. Type I interferons in infectious disease. Nat. Rev. Immunol. 15: 87-103.
17. Stifter, S. A., and C. G. Feng. 2015. Interfering with immunity: detrimental role of type I IFNs during infection. J. Immunol. 194: 2455-2465.
18. Manca, C., L. Tsenova, A. Bergtold, S. Freeman, M. Tovey, J. M. Musser, C. E. Barry, III, V. H. Freedman, and G. Kaplan. 2001. Virulence of a Mycobacterium tuberculosis clinical isolate in mice is determined by failure to induce Th1 type immunity and is associated with induction of IFN-a/b. Proc. Natl. Acad. Sci. USA 98: 5752-5757.
19. Manca, C., L. Tsenova, S. Freeman, A. K. Barczak, M. Tovey, P. J. Murray, C. Barry, and G. Kaplan. 2005. Hypervirulent M. tuberculosis W/Beijing strains upregulate type I IFNs and increase expression of negative regulators of the Jak-Stat pathway. J. Interferon Cytokine Res. 25: 694-701.
20. Ordway, D., M. Henao-Tamayo, M. Harton, G. Palanisamy, J. Troudt, C. Shanley, R. J. Basaraba, and I. M. Orme. 2007. The hypervirulent Mycobacterium tuberculosis strain HN878 induces a potent TH1 response followed by rapid down-regulation. J. Immunol. 179: 522-531.
21. Stanley, S. A., J. E. Johndrow, P. Manzanillo, and J. S. Cox. 2007. The type I IFN response to infection with Mycobacterium tuberculosis requires ESX-1-mediated secretion and contributes to pathogenesis. J. Immunol. 178: 3143-3152.
22. Dorhoi, A., V. Yeremeev, G. Nouailles, J. Weiner, III, S. Jö rg, E. Heinemann, D. Oberbeck-Müller, J. K. Knaul, A. Vogelzang, S. T. Reece, et al. 2014. Type I IFN signaling triggers immunopathology in tuberculosis-susceptible mice by modulating lung phagocyte dynamics. Eur. J. Immunol. 44: 2380-2393.
23. Antonelli, L. R., A. Gigliotti Rothfuchs, R. Gonçalves, E. Roffê, A. W. Cheever, A. Bafica, A. M. Salazar, C. G. Feng, and A. Sher. 2010. Intranasal Poly-IC treatment exacerbates tuberculosis in mice through the pulmonary recruitment of a pathogenpermissive monocyte/macrophage population. J. Clin. Invest. 120: 1674-1682.
24. McNab, F. W., J. Ewbank, R. Rajsbaum, E. Stavropoulos, A. Martirosyan, P. S. Redford, X. Wu, C. M. Graham, M. Saraiva, P. Tsichlis, et al. 2013. TPL-2- ERK1/2 signaling promotes host resistance against intracellular bacterial infection by negative regulation of type I IFN production. J. Immunol. 191: 1732-1743.
25. Mayer-Barber, K. D., B. B. Andrade, S. D. Oland, E. P. Amaral, D. L. Barber, J. Gonzales, S. C. Derrick, R. Shi, N. P. Kumar, W. Wei, et al. 2014. Hostdirected therapy of tuberculosis based on interleukin-1 and type I interferon crosstalk. Nature 511: 99-103.
26. Redford, P. S., K. D. Mayer-Barber, F. W. McNab, E. Stavropoulos, A. Wack, A. Sher, and A. O'Garra. 2014. Influenza A virus impairs control of Mycobacterium tuberculosis coinfection through a type I interferon receptor-dependent pathway. J. Infect. Dis. 209: 270-274.
27. Berry, M. P., C. M. Graham, F. W. McNab, Z. Xu, S. A. Bloch, T. Oni, K. A. Wilkinson, R. Banchereau, J. Skinner, R. J. Wilkinson, et al. 2010. An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature 466: 973-977.
28. Maertzdorf, J., D. Repsilber, S. K. Parida, K. Stanley, T. Roberts, G. Black, G. Walzl, and S. H. Kaufmann. 2011. Human gene expression profiles of susceptibility and resistance in tuberculosis. Genes Immun. 12: 15-22.
29. Ottenhoff, T. H., R. H. Dass, N. Yang, M. M. Zhang, H. E. Wong, E. Sahiratmadja, C. C. Khor, B. Alisjahbana, R. van Crevel, S. Marzuki, et al. 2012. Genome-wide expression profiling identifies type 1 interferon response pathways in active tuberculosis. PLoS One 7: e45839.
30. Cliff, J. M., J. S. Lee, N. Constantinou, J. E. Cho, T. G. Clark, K. Ronacher, E. C. King, P. T. Lukey, K. Duncan, P. D. Van Helden, et al. 2013. Distinct phases of blood gene expression pattern through tuberculosis treatment reflect modulation of the humoral immune response. J. Infect. Dis. 207: 18-29.
31. Bloom, C. I., C. M. Graham, M. P. Berry, K. A. Wilkinson, T. Oni, F. Rozakeas, Z. Xu, J. Rossello-Urgell, D. Chaussabel, J. Banchereau, et al. 2012. Detectable changes in the blood transcriptome are present after two weeks of antituberculosis therapy. PLoS One 7: e46191.
32. Mayer-Barber, K. D., B. B. Andrade, D. L. Barber, S. Hieny, C. G. Feng, P. Caspar, S. Oland, S. Gordon, and A. Sher. 2011. Innate and adaptive interferons suppress IL-1a and IL-1b production by distinct pulmonary myeloid subsets during Mycobacterium tuberculosis infection. Immunity 35: 1023-1034.
33. McNab, F. W., J. Ewbank, A. Howes, L. Moreira-Teixeira, A. Martirosyan, N. Ghilardi, M. Saraiva, and A. O'Garra. 2014. Type I IFN induces IL-10 production in an IL-27-independent manner and blocks responsiveness to IFN-g for production of IL-12 and bacterial killing in Mycobacterium tuberculosis-infected macrophages. J. Immunol. 193: 3600-3612.
34. Novikov, A., M. Cardone, R. Thompson, K. Shenderov, K. D. Kirschman, K. D. Mayer-Barber, T. G. Myers, R. L. Rabin, G. Trinchieri, A. Sher, and C. G. Feng. 2011. Mycobacterium tuberculosis triggers host type I IFN signaling to regulate IL-1b production in human macrophages. J. Immunol. 187: 2540-2547.
35. Mariotti, S., R. Teloni, E. Iona, L. Fattorini, G. Romagnoli, M. C. Gagliardi, G. Orefici, and R. Nisini. 2004. Mycobacterium tuberculosis diverts alpha interferon-induced monocyte differentiation from dendritic cells into immunoprivileged macrophage-like host cells. Infect. Immun. 72: 4385-4392.
36. Mayer-Barber, K. D., and A. Sher. 2015. Cytokine and lipid mediator networks in tuberculosis. Immunol. Rev. 264: 264-275.
37. Teles, R. M., T. G. Graeber, S. R. Krutzik, D. Montoya, M. Schenk, D. J. Lee, E. Komisopoulou, K. Kelly-Scumpia, R. Chun, S. S. Iyer, et al. 2013. Type I interferon suppresses type II interferon-triggered human anti-mycobacterial responses. Science 339: 1448-1453.
38. de Paus, R. A., A. van Wengen, I. Schmidt, M. Visser, E. M. Verdegaal, J. T. van Dissel, and E. van de Vosse. 2013. Inhibition of the type I immune responses of human monocytes by IFN-a and IFN-b. Cytokine 61: 645-655.
39. Desvignes, L., A. J. Wolf, and J. D. Ernst. 2012. Dynamic roles of type I and type II IFNs in early infection with Mycobacterium tuberculosis. J. Immunol. 188: 6205-6215.
40. Ward, C. M., H. Jyonouchi, S. V. Kotenko, S. V. Smirnov, R. Patel, H. Aguila, G. McSherry, B. Dashefsky, and S. M. Holland. 2007. Adjunctive treatment of disseminated Mycobacterium avium complex infection with interferon alpha-2b in a patient with complete interferon-gamma receptor R1 deficiency. Eur. J. Pediatr. 166: 981-985.
41. Cooper, A. M., J. E. Pearl, J. V. Brooks, S. Ehlers, and I. M. Orme. 2000. Expression of the nitric oxide synthase 2 gene is not essential for early control of Mycobacterium tuberculosis in the murine lung. Infect. Immun. 68: 6879-6882.
42. Jung, Y. J., R. LaCourse, L. Ryan, and R. J. North. 2002. Virulent but not avirulent Mycobacterium tuberculosis can evade the growth inhibitory action of a T helper 1-dependent, nitric oxide synthase 2-independent defense in mice. J. Exp. Med. 196: 991-998.
43. Gomes, M. S., M. Flórido, T. F. Pais, and R. Appelberg. 1999. Improved clearance of Mycobacterium avium upon disruption of the inducible nitric oxide synthase gene. J. Immunol. 162: 6734-6739.
44. Winkler, F., U. Koedel, S. Kastenbauer, and H. W. Pfister. 2001. Differential expression of nitric oxide synthases in bacterial meningitis: role of the inducible isoform for blood-brain barrier breakdown. J. Infect. Dis. 183: 1749-1759.
45. Cole, C., S. Thomas, H. Filak, P. M. Henson, and L. L. Lenz. 2012. Nitric oxide increases susceptibility of Toll-like receptor-activated macrophages to spreading Listeria monocytogenes. Immunity 36: 807-820.
46. MacMicking, J., Q. W. Xie, and C. Nathan. 1997. Nitric oxide and macrophage function. Annu. Rev. Immunol. 15: 323-350.
47. Ehrt, S., D. Schnappinger, S. Bekiranov, J. Drenkow, S. Shi, T. R. Gingeras, T. Gaasterland, G. Schoolnik, and C. Nathan. 2001. Reprogramming of the macrophage transcriptome in response to interferon-g and Mycobacterium tuberculosis: signaling roles of nitric oxide synthase-2 and phagocyte oxidase. J. Exp. Med. 194: 1123-1140.
48. El Kasmi, K. C., J. E. Qualls, J. T. Pesce, A. M. Smith, R. W. Thompson, M. Henao-Tamayo, R. J. Basaraba, T. König, U. Schleicher, M. S. Koo, et al. 2008. Toll-like receptor-induced arginase 1 in macrophages thwarts effective immunity against intracellular pathogens. Nat. Immunol. 9: 1399-1406.
49. Monin, L., K. L. Griffiths, W. Y. Lam, R. Gopal, D. D. Kang, M. Ahmed, A. Rajamanickam, A. Cruz-Lagunas, J. Zúñiga, S. Babu, et al. 2015. Helminthinduced arginase-1 exacerbates lung inflammation and disease severity in tuberculosis. J. Clin. Invest. 125: 4699-4713.
50. Murray, P. J., and T. A. Wynn. 2011. Protective and pathogenic functions of macrophage subsets. Nat. Rev. Immunol. 11: 723-737.
51. Bronte, V., and P. Zanovello. 2005. Regulation of immune responses by L-arginine metabolism. Nat. Rev. Immunol. 5: 641-654.
52. Giosué, S., M. Casarini, L. Alemanno, G. Galluccio, P. Mattia, G. Pedicelli, L. Rebek, A. Bisetti, and F. Ameglio. 1998. Effects of aerosolized interferon-a in patients with pulmonary tuberculosis. Am. J. Respir. Crit. Care Med. 158: 1156-1162.
53. Palmero, D., K. Eiguchi, P. Rendo, L. Castro Zorrilla, E. Abbate, and L. J. González Montaner. 1999. Phase II trial of recombinant interferon-a2b in patients with advanced intractable multidrug-resistant pulmonary tuberculosis: long-term follow-up. Int. J. Tuberc. Lung Dis. 3: 214-218.
54. Bax, H. I., A. F. Freeman, L. Ding, A. P. Hsu, B. Marciano, E. Kristosturyan, T. Jancel, C. Spalding, J. Pechacek, K. N. Olivier, et al. 2013. Interferon alpha treatment of patients with impaired interferon gamma signaling. J. Clin. Immunol. 33: 991-1001.
55. Chan, J., K. Tanaka, D. Carroll, J. Flynn, and B. R. Bloom. 1995. Effects of nitric oxide synthase inhibitors on murine infection with Mycobacterium tuberculosis. Infect. Immun. 63: 736-740.
56. Denis, M. 1991. Interferon-gamma-treated murine macrophages inhibit growth of tubercle bacilli via the generation of reactive nitrogen intermediates. Cell. Immunol. 132: 150-157.
57. Gao, J. J., M. B. Filla, M. J. Fultz, S. N. Vogel, S. W. Russell, and W. J. Murphy. 1998. Autocrine/paracrine IFN-alphabeta mediates the lipopolysaccharide-induced activation of transcription factor Stat1a in mouse macrophages: pivotal role of Stat1a in induction of the inducible nitric oxide synthase gene. J. Immunol. 161: 4803-4810.
58. Mishra, B. B., V. A. Rathinam, G. W. Martens, A. J. Martinot, H. Kornfeld, K. A. Fitzgerald, and C. M. Sassetti. 2013. Nitric oxide controls the immunopathology of tuberculosis by inhibiting NLRP3 inflammasome-dependent processing of IL-1b. Nat. Immunol. 14: 52-60.
59. Pessanha, A. P., R. A. Martins, A. L. Mattos-Guaraldi, A. Vianna, and L. O. Moreira. 2012. Arginase-1 expression in granulomas of tuberculosis patients. FEMS Immunol. Med. Microbiol. 66: 265-268.
60. Qualls, J. E., G. Neale, A. M. Smith, M. S. Koo, A. A. DeFreitas, H. Zhang, G. Kaplan, S. S. Watowich, and P. J. Murray. 2010. Arginine usage in mycobacteria-infected macrophages depends on autocrine-paracrine cytokine signaling. Sci. Signal. 3: ra62.
61. Wanasen, N., and L. Soong. 2008. L-arginine metabolism and its impact on host immunity against Leishmania infection. Immunol. Res. 41: 15-25.
62. Kahnert, A., P. Seiler, M. Stein, S. Bandermann, K. Hahnke, H. Mollenkopf, and S. H. Kaufmann. 2006. Alternative activation deprives macrophages of a coordinated defense program to Mycobacterium tuberculosis. Eur. J. Immunol. 36: 631-647.
63. Potian, J. A., W. Rafi, K. Bhatt, A. McBride, W. C. Gause, and P. Salgame. 2011. Preexisting helminth infection induces inhibition of innate pulmonary antituberculosis defense by engaging the IL-4 receptor pathway. J. Exp. Med. 208: 1863-1874.
64. Heitmann, L., M. Abad Dar, T. Schreiber, H. Erdmann, J. Behrends, A. N. Mckenzie, F. Brombacher, S. Ehlers, and C. Hölscher. 2014. The IL-13/IL- 4Ra axis is involved in tuberculosis-associated pathology. J. Pathol. 234: 338-350.
65. Kratochvill, F., G. Neale, J. M. Haverkamp, L. A. Van de Velde, A. M. Smith, D. Kawauchi, J. McEvoy, M. F. Roussel, M. A. Dyer, J. E. Qualls, and P. J. Murray. 2015. TNF counterbalances the emergence of M2 tumor macrophages. Cell Reports 12: 1902-1914.
66. Schreiber, T., S. Ehlers, L. Heitmann, A. Rausch, J. Mages, P. J. Murray, R. Lang, and C. Hölscher. 2009. Autocrine IL-10 induces hallmarks of alternative activation in macrophages and suppresses antituberculosis effector mechanisms without compromising T cell immunity. J. Immunol. 183: 1301-1312